Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31711236 | 0.74 | P2RY6 (0.41) | P2RY6 | |
| SCHEMBL3200612 | 0.74 | P2RY6 (0.41) | P2RY6 | |
| SCHEMBL472055 | 0.73 | NPC1 (0.37) | P2RY6TMEM97DRD5ADRA2ASIGMAR1 | |
| SCHEMBL9392813 | 0.73 | P2RY6 (0.41) | P2RY6DRD5 | |
| SCHEMBL11296635 | 0.71 | — | — | |
| SCHEMBL9118213 | 0.71 | CYP1A2 (0.31) | — | |
| SCHEMBL5552767 | 0.68 | MAPT (0.42) | — | |
| SCHEMBL9562071 | 0.66 | RAB9A (0.35) | P2RY6DRD5ADRA2A | |
| SCHEMBL1428264 | 0.66 | CYP1A2 (0.36) | — | |
| SCHEMBL4624307 | 0.65 | MAPT (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5242974-A | Polymer formation on substrate with tether molecule, unmasking of protective group to form cyclic polymer, bond clevage | AFFYMAX TECHNOLOGIES N.V. (NL) | 1993-09-07 | — | — | US | claimed |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240092799-A1 | MNK INHIBITORS | HEPAGENE THERAPEUTICS HK LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| EP-4271510-A1 | METHODS AND COMPOSITIONS FOR LIGHT-CONTROLLED SURFACE PATTERNING USING A POLYMER | 10X Genomics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4271509-A1 | MOLECULAR ARRAYS AND METHODS FOR GENERATING AND USING THE ARRAYS | 10X Genomics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116794200-A | Detection method of piperonal related substances | 宜昌天仁药业有限责任公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116490505-A | MNK inhibitors | 和博医药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11708374-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) | 2023-07-25 | — | — | US | disclosed |
| US-5359115-A | Reacting phosphonic monoester with dialkylazodicarboxylate, triphenylphosphine and secondary alcohol to form diester, hydrolyzing selective ester to form monoester, coupling an aminoacid to yield peptidylphosphonate | AFFYMAX TECHNOLOGIES, N.V. (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994010128-A1 | NOVEL PHOTOREACTIVE PROTECTING GROUPS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1994-05-11 | — | — | WO | disclosed |
| WO-1994006808-A1 | METHODS FOR THE SYNTHESIS OF PHOSPHONATE ESTERS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1994-03-31 | — | — | WO | disclosed |
| WO-1994006291-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF COMPOUNDS ON A SOLID SUPPORT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0562025-A4 | — | — | 1994-03-30 | — | — | EP | disclosed |
| US-5288514-A | Linking a protected 2-aminobenzophenone to a substrate; deprotecting and reacting with an amino acid; cyclization; removal from substrate; screening | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-02-22 | — | — | US | disclosed |
| EP-0562025-A1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-09-29 | — | — | EP | disclosed |
| US-5242974-A | Polymer formation on substrate with tether molecule, unmasking of protective group to form cyclic polymer, bond clevage | AFFYMAX TECHNOLOGIES N.V. (NL) | 1993-09-07 | — | — | US | disclosed |
| WO-1993010161-A1 | POLYMER REVERSAL ON SOLID SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-05-27 | — | — | WO | disclosed |
| WO-1992010092-A1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092799-A1 | MNK INHIBITORS | MKNK1, MATK, NEK1 | P2RY6 4096/4885TMEM97 3827/4885DRD5 4842/4885 |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | P2RY6 1070/4885TMEM97 4174/4885DRD5 734/4885 |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, ABL1, LYN | P2RY6 2538/4885TMEM97 3369/4885DRD5 4131/4885 |
| US-11708374-B2 | Preparation of condensed triazepine derivatives and their use as BET inhibitors | BET1, EP300, BICRA | P2RY6 3652/4885TMEM97 4016/4885DRD5 2308/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | P2RY6 4016/4885TMEM97 4449/4885DRD5 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.